Case study: Treating COVID-19 in a patient with multiple myeloma

(American Society of Hematology) A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may be an effective COVID-19 treatment for very ill patients who also have multiple myeloma and other blood cancers. The report, published in Blood Advances, also suggests that blood cancer patients may have atypical COVID-19 symptoms.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news

Related Links:

With COVID-19 becoming the number one priority for researchers around the globe, Parham Hashemi describes his role in overseeing the new trials being launched during the pandemic.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 30 May 2020Source: Indian Heart JournalAuthor(s): Aditya Kapoor, Rakesh Yadav
Source: Indian Heart Journal - Category: Cardiology Source Type: research
Getty Images ... Hair salons, restaurants and retail shops are slowly reopening for business in communities throughout the country. ... And this summer many pools will join them, contingent on guid...
Source: AARP.org News - Category: American Health Source Type: news
Publication date: Available online 30 May 2020Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Renjie Wang, Zhengwei Cao, Lan Wei, Lin Bai, Hui Wang, Shiyi Zhou, Shuyue Zhan, Bin Ji, Zibo Li, Shi Gao, Jin Xie, Qingjie Ma
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
(American Association for Cancer Research) Among patients with both colorectal cancer and diabetes in Korea, those who had a high adherence to their oral diabetes medication had a significantly reduced risk of overall mortality compared with those with lower adherence.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Last week I was contacted by Stephen Quinn, a Ph.D. student at Queen’s University in Belfast. He informed me about a study called IMPaCCT whose intent is to look at the effect that the current Covid-19 crisis has had, and is having, on pre-cancer, cancer and rare disease patients and their caregivers. The researchers, which include Stephen, hope to be able to use this data to inform patients and caregivers, as well as publish their findings in scientific journals. He asked for my help in reaching out to smoldering myeloma and MGUS patients. Of course! So, how can we help? By taking their online SURVEY. I am about to...
Source: Margaret's Corner - Category: Cancer & Oncology Authors: Tags: Blogroll ImpaCCt study Source Type: blogs
Researchers say selinexor, which is currently approved treat multiple myeloma, blocks a protein that allows coronavirus to multiply in our cells and plays a role in the inflammatory response.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
New Brunswick, N.J. (April 14, 2020) – Johnson &Johnson (NYSE: JNJ) today announced results for first-quarter 2020. The Company also announced earlier today that its Board of Directors declared a 6.3% increase in the quarterly dividend rate, from $0.95 per share to $1.01 per share. At the new rate, the indicated dividend on an annual basis is $4.04 per share compared to the previous rate of $3.80 per share. “With Johnson &Johnson’s century-plus history of leading in times of great challenge, we are mobilizing our resources across the Company in the fight against the COVID-19 pandemic,” said ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
Authors: Salako O, Okunade K, Allsop M, Habeebu M, Toye M, Oluyede G, Fagbenro G, Salako B Abstract On Monday, 23 March 2020, Nigeria recorded its first mortality from the novel global COVID-19 outbreak. Before this, the country reported 36 confirmed cases (at the time of writing) and has discharged home two cases after weeks of care at a government-approved isolation centre in Lagos State. This first mortality was that of a 67-year-old man with a history of multiple myeloma, a type of blood cancer. He was undergoing chemotherapy and had just returned to Nigeria following medical treatment in the United Kingdom. Th...
Source: Ecancermedicalscience - Category: Cancer & Oncology Tags: Ecancermedicalscience Source Type: research
A case study of a patient in Wuhan, China demonstrated that tocilizumab may be an effective treatment for very ill patients with COVID-19 who also have multiple myeloma and other blood cancers.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
More News: Actemra | Cancer | Cancer & Oncology | China Health | COVID-19 | Hematology | Infectious Diseases | Myeloma | Study